Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...

Shields has been vocal about women's wellness and now backs an initiative for women to be aware of an infection that's ...

Australians ages 18 to 64 who are classed as "moderate to high risk" will be able to get the shingles jab. ...

GSK plc (LSE/NYSE: GSK) is partnering with Brooke Shields, as part of its THRIVE@50+ campaign, to encourage people 50 and ...

PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

4 PHN is the most common complication of shingles, occurring in 5–30% of all shingles cases, from findings in various studies.5 GSK cautions investors that any forward-looking statements or ...

Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.

6 Shingles is a painful, blistering rash that can last for weeks ... Vaccination with AREXVY may not result in protection of all vaccine recipients. Please see full Prescribing Information for AREXVY.